Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

MIAMI, FL — The FGC2.3: Feline Vocalization Classification and Cat Translation Project, authored by Dr. Vladislav Reznikov, has crossed a critical scientific milestone — surpassing 14,000 reads on ResearchGate and rapidly climbing toward record-setting levels in the field of animal communication and artificial intelligence. This pioneering work aims to develop the world’s first scientifically grounded…

Tariff-Free Relocation to the US

Tariff-Free Relocation to the US

EU, China, and more are now in the crosshairs. How’s next? It’s time to act. The Trump administration has announced sweeping tariff hikes, as high as 50%, on imports from the European Union, China, and other major markets. Affected industries? Pharmaceuticals, Biotech, Medical Devices, IVD, and Food Supplements — core sectors now facing crippling costs,…

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

This study presents the GDP Matrix by Dr. Vlad Reznikov, a bubble chart designed to clarify the complex relationships between GDP, PPP, and population data by categorizing countries into four quadrants—ROCKSTARS, HONEYBEES, MAVERICKS, and UNDERDOGS depending on National Regulatory Authorities (NRAs) Maturity Level (ML) of the regulatory affairs requirements for healthcare products. Find more details…

Xiangyi Cheng Introduces Augmented Reality to Educational and Healthcare Settings

Xiangyi Cheng Introduces Augmented Reality to Educational and Healthcare Settings

When Xiangyi Cheng published her first journal paper as a principal investigator in IEEE Access in 2024, it marked more than a professional milestone. For Cheng, an IEEE member and an assistant professor of mechanical engineering at Loyola Marymount University, in Los Angeles, it was the latest waypoint in a career shaped by curiosity, persistence, and a belief that technology should serve people—not the other way around.

The paper’s title was “Mobile Devices or Head-Mounted Displays: A Comparative Review and Analysis of Augmented Reality in Healthcare.”

XIANGYI CHENG

Employer

Loyola Marymount University, in Los Angeles

Title

Assistant professor of mechanical engineering

Member grade

Member

Alma maters

China University of Mining and Technology; Texas A&M University

Cheng’s work spans robotics, intelligent systems, human-machine interaction and artificial intelligence. It has applications in patient-specific surgical planning, an approach whereby treatment is customized to the anatomy and clinical needs of each individual.

Her research also covers wearables for rehabilitation and augmented-reality-enhanced engineering education.

The throughline of her career is sound judgment based on critical thinking. She urges her students to avoid the temptation to accept the answers they’re given by AI without cross-checking them against their own foundational understanding of the subject matter.

“AI can give you ideas,” Cheng says, “but it should never lead your thinking.”

That principle—honed through uncertainty, disciplinary shifts, and hard-earned confidence—has made Cheng an emerging voice in applied intelligent systems and a thoughtful educator preparing students for an AI-saturated world.

From Xi’an to Beijing: A mind drawn to mathematics

Cheng, born in Xi’an, China, grew up in a household shaped by her parents’ disparate careers. Her father was a mining engineer, and her mother taught Chinese and literature at a high school.

“That contrast between logical and literary thinking helped me understand myself early,” Cheng says. “I liked math, and STEM felt natural to me.”

Several teachers reinforced her inclination, she says, particularly a math teacher whose calm, fair approach emphasized reasoning over punishments such as detention for misbehavior or failure to complete assignments.

“It wasn’t about being right,” Cheng says. “It was about thinking clearly.”

She moved to Beijing in 2011 to attend the China University of Mining and Technology , where she studied mechanical engineering. After graduating with a bachelor’s degree in 2015, she was unsure where the field would take her.

An IEEE paper changed her trajectory

Later in 2015, she traveled to the United States to study at Case Western Reserve University, in Cleveland.

She initially viewed the move as exploratory rather than a long-term commitment.

“I wasn’t thinking about a Ph.D.,” she says. “I wasn’t even sure research was for me.”

That uncertainty shifted in 2017, when Cheng submitted her “IntuBot: Design and Prototyping of a Robotic Intubation Device” paper to the IEEE International Conference on Robotics and Automation (ICRA)—which was accepted.

“AI can give you more possibilities, but thinking is still our responsibility.”

Intubation is a procedure in which an endotracheal tube is inserted into a patient’s airway—usually through the mouth—to help them breathe. Because placing the tube correctly is not simple and usually must be done quickly, it requires training. That’s why research into robotic or assisted intubation systems focuses on improving speed, accuracy, and safety.

She presented her findings at ICRA in 2018, giving her early exposure to a global research community.

“That acceptance gave me confidence,” she recalls. “It showed me I could contribute to the field.”

Her advisor at Case Western encouraged her to switch from the mechanical engineering master’s program to the Ph.D. track. When the advisor moved to Texas A&M University, in College Station, in 2019, Cheng decided to transfer. She completed her Ph.D. in mechanical engineering at Texas A&M in 2022.

Although she didn’t earn a degree from Case Western, she credits her experience there with clarifying her professional direction.

Shortly after graduating with her Ph.D., Cheng was hired as an assistant professor of mechanical engineering at Ohio Northern University, in Ada. She left in 2024 to become an assistant professor at Loyola Marymount.

Engineering for the body—and the classroom

Cheng’s research focuses on human-centered engineering, particularly in health care. One of her major projects addresses syndactyly, a congenital condition in which a newborn’s fingers are fused at birth. Surgeons rely on their experience to estimate the size and shape of skin grafts to be taken from another part of the body for the corrective surgery.

She is developing technology to scan the patient’s hand, extract anatomical landmarks, and use finite element analysis—a computer-based method for predicting how a physical object will behave under real-world conditions—to determine the optimal graft size and shape.

Smiling portrait of Xiangyi Cheng. Xiangyi Cheng designs human-centered intelligent systems with applications in health care and education.Xiangyi Cheng

“Everyone’s hand is different,” Cheng says. “So the surgery should be personalized.”

Another project centers on developing smart gloves to assist with hand rehabilitation, pairing the unaffected hand with the injured one so the person’s natural motion can help guide therapy.

She also is exploring augmented reality in engineering education, using immersive visualization and AI tools to help students grasp three-dimensional concepts that are difficult to convey through traditional learning tools. Such visualization lets students see and interact with a digital world as if they’re inside it instead of viewing it on a flat screen.

Teaching balance in an AI-driven world

Despite working at the forefront of AI-enabled systems, Cheng cautions her students to be judicious in their use of the technology so that they don’t rely on it too heavily.

“AI is not always right and perfect,” she says. “You still need to be able to judge whether the answers it provides are correct.”

As AI continues to reshape engineering, Cheng remains grounded in a simple principle, she says: “We should use these tools. But we should never let them replace our judgment. AI can give you more possibilities, but thinking is still our responsibility.”

In her lab and classroom, Cheng prioritizes independent thinking, critical evaluation, and persistence. Many of her research students are undergraduates, and she encourages them to take ownership of their work—planning ahead, testing ideas, and learning from failure.

“The students who succeed don’t give up easily,” she says.

What she finds most rewarding, she says, is watching students mature. Reserved first-year students often become confident seniors who can present complex work and manage demanding projects.

“Getting to witness that transformation is why I teach,” she says.

For students considering engineering, Cheng offers straightforward advice: “Focus on mathematics. Engineering looks hands-on, but math is the foundation behind everything.”

With practice and persistence, she says, students can succeed and find meaning in the field.

Why IEEE continues to matter

Cheng joined IEEE in 2017, the year she submitted her first paper to ICRA. The organization has remained central to her professional development, she says.

She has served as a reviewer for IEEE journals and conferences including Robotics and Automation Letters, Transactions on Medical Robotics and Bionics, Transactions on Robotics, the International Conference on Intelligent Robots and Systems, and ICRA.

IEEE’s interdisciplinary scope aligns naturally with her work, she says, adding that the organization is “one of the few places that truly welcomes research across boundaries.”

More personally, IEEE helped her see a future she had not initially imagined.

“That first conference was a turning point,” she says. “It helped me realize I belonged.”

Overview of Clinical Testing: HYRNUO Insights

Overview of Clinical Testing: HYRNUO Insights

HYRNUO is a tyrosine-kinase inhibitor that is indicated for the treatment of adult patients with non-squamous non-small cell lung cancer. Learn more about the drug trials.

Exploring Adhesion Strength, Compatibility with Biological Systems, and More

Exploring Adhesion Strength, Compatibility with Biological Systems, and More

Designing a medical device? This whitepaper helps you evaluate adhesive options for biocompatibility, sterilization resistance, and manufacturability — so you can make the right material decision early.

What Attendees will Learn

  1. How to select between epoxy, silicone, cyanoacrylate, and UV/LED curable adhesives based on your device requirements
  2. Which adhesive systems meet USP Class VI and ISO 10993-5 biocompatibility standards
  3. How different sterilization methods, such as autoclaving, EtO, gamma, chemical immersion affect adhesive performance over repeated cycles
  4. Why integrating adhesive selection early in the design process reduces costly trade-offs between performance and manufacturability
  5. Download this free whitepaper now!

Download this free whitepaper now!

Summary of Key Outcomes from the CHMP Meeting on Medicinal Products for Human Use, Held from February 23 to 26, 2026

Summary of Key Outcomes from the CHMP Meeting on Medicinal Products for Human Use, Held from February 23 to 26, 2026

12 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its February 2026 meeting.The committee recommended…, CHMP statistics Key figures from the February 2026 CHMP meeting are represented in the graphic below. , CHMP statistics:…, Positive recommendations on new medicines, mCombriax Common name Influenza and COVID 19, mRNA vaccine Marketing authorisation applicant Moderna Biotech Spain S.L. Therapeutic indication Immunisation…, Ojemda INN tovorafenib  Marketing authorisation applicant Ipsen Pharma  Therapeutic indication Treatment of paediatric low-grade glioma (LGG).…, Onerji INN levodopa / carbidopa  Marketing authorisation applicant Tanabe Pharma GmbH Therapeutic indication Treatment of motor fluctuations in patients…, Palsonify INN paltusotine Marketing authorisation applicant Crinetics Pharmaceuticals Europe GmbH Therapeutic indication Medical treatment of adult patients…, Rhapsido INN remibrutinib Marketing authorisation applicant Novartis Europharm Limited Therapeutic indication Treatment of chronic spontaneous urticaria (CSU…, Xolremdi INN mavorixafor Marketing authorisation applicant X4 Pharmaceuticals (Austria) GmbH Therapeutic indication Treatment of WHIM syndrome. More…, Positive recommendations on new biosimilar medicines, Bysumlog INN insulin lispro  Marketing authorisation holder Gan & Lee Pharmaceuticals Europe GmbH Therapeutic indication Treatment of diabetes…, Dazparda INN insulin aspart  Marketing authorisation applicant Gan & Lee Pharmaceuticals Europe GmbH Therapeutic indication Treatment of diabetes…, Fubelv INN etanercept  Marketing authorisation holder Biosimilar Collaborations Ireland Limited Therapeutic indication Treatment of rheumatoid arthritis…, Poherdy INN pertuzumab Marketing authorisation holder Organon N.V. Therapeutic indication Treatment of breast cancer in adults.  More information…, Tuyory INN tocilizumab  Marketing authorisation holder Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.) Therapeutic indication Treatment of…, Zandoriah INN teriparatide  Marketing authorisation holder Cinnagen Co Unipessoal Lda. Therapeutic indication Treatment of osteoporosis. More…, Positive opinions for medicines intended for use outside EU, Acoziborole Winthrop International non-proprietary name (INN) acoziborole  Marketing authorisation applicant Sanofi Winthrop Industrie  Therapeutic…, Negative recommendation on new medicines, Daybu INN trofinetide Marketing authorisation holder Acadia Pharmaceuticals (Netherlands) B.V. Orphan designation This medicine was designated an orphan…, Iloperidone Vanda Pharmaceuticals INN iloperidone  Marketing authorisation holder Vanda Pharmaceuticals Netherlands B.V. More information Iloperidone…, Positive recommendations on extensions of therapeutic indications , Dupixent INN dupilumab  Marketing authorisation holder Sanofi Winthrop Industrie More information Dupixent : pending EC decision, Jorveza INN budesonide  Market authorisation holder Dr. Falk Pharma GmbH More information Jorveza : pending EC decision, Keytruda INN pembrolizumab Market authorisation holder Merck Sharp & Dohme B.V. More information Keytruda : pending EC decision, Olumiant INN baricitinib Market authorisation holder Eli Lilly Nederland B.V. More information Olumiant : pending EC decision, Scemblix INN asciminib Market authorisation holder Novartis Europharm Limited More information Scemblix : pending EC decision, Stelara INN ustekinumab Market authorisation holder Janssen-Cilag International NV More information Stelara : pending EC decision, Withdrawals of initial marketing authorisation application, Zumrad INN sasanlimab  Marketing authorisation applicant Pfizer Europe MA EEIG More information Zumrad : pending EC decision

Lilly Surpasses Novo Once More in Weight Loss, Now with an Oral Solution

Lilly Surpasses Novo Once More in Weight Loss, Now with an Oral Solution

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly’s orforglipron bested Novo’s oral semaglutide in blood sugar control and weight reduction—albeit with a few extra discontinuations as compared to its rival.